Atrial fibrillation and stroke: Four treatment controversies

Current Treatment Options in Neurology

Volumn 7, Issue 6, 2005, Pages 491-498

  Hart, Robert G ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; CLOPIDOGREL; IBUPROFEN; IDRAPARINUX; NAPROXEN; PARACETAMOL; PLACEBO; TRIFLUSAL; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG CHOICE; DYSPEPSIA; ELDERLY CARE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER TOXICITY; LOW DRUG DOSE; META ANALYSIS; NAUSEA; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR;

EID: 28044444337     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-005-0049-4     Document Type: Review

References (39)

1. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke. The Framingham Study. Stroke 1991, 22:983-988.
2. Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999, 131:492-501.
3. Go AS, Hylek EM, Chang Y, et al.: Anticoagulation therapy for stroke prevention in atrial fibrillation. How well do randomized trials translate into clinical practice? JAMA 2003, 290:2685-2692.
4. Gage BF, van Walraven C, Pearce LA, et al.: Selecting patients with atrial fibrillation for anticoagulation. Stroke risk stratification in patients taking aspirin. Circulation 2004, 110:2287-2292.
5. Hart RG, Pearce LA, Koudstaal PJ: Transient ischemic attacks in patients with atrial fibrillation. Implications for secondary prevention. Stroke 2004, 35:948-951.
6. Sherman DG, Kim SG, Boop BS, et al.: The occurrence and characteristics of stroke events in the AFFIRM study. Arch Intern Med 2005, 165:1185-1191.
7. Marini C, De Santis F, Sacco S, et al.: Contribution of atrial fibrillation to incidence and outcome of ischemic stroke. Results from a population-based study. Stroke 2005, 36:1115-1119.
8. Hart RG, Pearce LA, Miller Vr, et al.: Cardioembolic vs. noncardioembolic stroke in atrial fibrillation: frequency and effect of antithrombotic agents. Cerebrovasc Dis 2000, 10:39-43.
9. Olsson SB, Executive Steering Committee on behalf of the SPORTIF III Investigators: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation: randomized controlled trial. Lancet 2003, 362:1691-1698.
10. SPORTIF Executive Steering Committee for the SPORTIF V Investigators: Ximelagatran vs. warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA 2005, 293:690-698.
11. Akins P, Zoble R, Haley JA, et al.: Efficacy of ximelagatran for secondary stroke prevention in atrial fibrillation: pooled analysis of the SPORTIF III and V clinical trial results [abstract]. Stroke 2005, 36:423.
12. Gomberg-Maitland M, Frison L, Halperin JL: Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality. Am Heart J 2003, 146:398-403.
13. AstraZeneca International: AstraZeneca receives action letter from FDA for Exanta (ximelagatran), October 11, 2004 [press release]. http://www.astrazeneca.com/pressrelease/3285.aspx. Accessed March 16, 2005.
14. Hohnloser SH, Connolly SJ: Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues. J Cardiovasc Electrophysiol 2003, 14(Suppl 9):S60-S63.
15. Hart RG, Halperin JL, Pearce LA, et al.: Lessons from the Stroke Prevention in Atrial Fibrillation Trials. Ann Intern Med 2003, 138:831-838.
16. Gage BF, Waterman AD, Shannon W, et al.: Validation of clinical classification schemes for predicting stroke: results of the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
17. Oden A, Fahlen M, Hart RG: Optimal INR for prevention of stroke and mortality in atrial fibrillation: a critical appraisal. Thromb Res 2005, In press.
18. The effect of low-dose warfarin on the risk of stroke in nonrheumatic atrial fibrillation. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990, 323:1505-1511.
19. Ezekowitz MD, Bridgers SL, James KE, et al.: Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992, 327:1406-1412.
20. Hart RG, Tonarelli SB, Pearce LA: Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005, 36:1588-1593.
21. Fang MC, Chang Y, Hylek EM, et al.: Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004, 141:745-752.
22. Hylek EM, Go AS, Chang Y, et al.: Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003, 349:1019-1026.
23. Hart RG: Intensity of anticoagulation to prevent stroke in patients with atrial fibrillation. Ann Intern Med 1998, 128:408.
24. Singer DE, Albers GW, Dalen JE, et al.: Antithrombotic therapy in atrial fibrillation. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:429S-456S.
25. Bleeding during antithrombotic therapy in atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med 1996, 156:409-416.
26. Johnson CE, Lim WK, Workman BS: People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up. J Am Geriatr Soc 2005, 53:655-659.
27. Fuster V, Ryden LE, Asinger RW, et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. Circulation 2001, 104:2118-2150.
28. Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF: Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 2004, 35:2362-2367.
29. Hart RG, Benavente O, Pearce LA: Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis 1999, 9:215-217.
30. Berwaerts J, Webster J: Analysis of risk factors involved in oral-anticoagulant-related intracranial hemorrhages. Q J Med 2000, 93:513-521.
31. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Stroke Prevention in Atrial Fibrillation Investigators. Lancet 1996, 348:633-638.
32. Lechat P, Lardoux H, Mallet A, et al.: Anticoagulant (flunidone)-aspirin combination in patients with high risk atrial fibrillation. A randomized trial (Fluindone, Fibrillation Auriculaire, Aspirin et Contrast Spontane; FEAACS). Carebrovasc Dis 2001, 12:245-252.
33. Perez-Gomez F, Alegria E, Berjon J, et al.: Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular atrial fibrillation and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004, 44:1557-1566.
34. Falk RH: Reconsidering combined antiplatelet and anticoagulant therapy in atrial fibrillation. J Am Coll Cardiol 2004, 44:1567-1569.
35. Chapman N, Huxley R, Anderson C, et al.: Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history. The PROGRESS trial. Stroke 2004, 35:116-121.
36. Stollberger C, Finsterer J: Primary and secondary stroke prevention in nonrheumatic atrial fibrillation by oral anticoagulation. Eur Neurol 2003, 50:127-135.
37. Schulman S, Beyth RJ: Risk of bleeding with long-term antithrombotic therapy in atrial fibrillation. Eur Heart J Suppl 2005, 7(Suppl C):C34-C40.
38. Miller PSJ, Drummond MF, Langkilde LK, et al.: Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation. Eur Heart J Suppl 2005, 7(Suppl C):C41-C54.
39. Miller PSJ, Andersson FL, Kalra L: Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated? Stroke 2005, 36:360-366.